Free Trial
NASDAQ:CTNM

Contineum Therapeutics Q2 2024 Earnings Report

Contineum Therapeutics logo
$3.86 +0.03 (+0.78%)
Closing price 05/21/2025 04:00 PM Eastern
Extended Trading
$4.11 +0.25 (+6.45%)
As of 05/21/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.37
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Contineum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Contineum Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:00AM ET

Earnings Documents

Contineum Therapeutics Earnings Headlines

Warning: Prepare to Be Shocked by These Payouts
There's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don't even pay dividends. It's fast, it's legal, and most people have no clue it exists.
See More Contineum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email.

About Contineum Therapeutics

Contineum Therapeutics (NASDAQ:CTNM), a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

View Contineum Therapeutics Profile

More Earnings Resources from MarketBeat